Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam

Mojica, María F; Papp-Wallace, Krisztina M.; Taracila, Magdalena A.; Barnes, Melissa D.; Rutter, Joseph; Jacobs, Michael; LiPuma, John J.; Walsh, Thomas J.; Vila, Alejandro J.; Bonomo, Robert A.

doi:10.1128/aac.00777-17

Cited by 58 publications

(43 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a modified carbapenemase multiplex PCR that detects bla IMP , bla NDM , bla OXA-48-like, and bla VIM was employed (26). The P. aeruginosa and S. maltophilia ␤-lactamase content was previously determined in other studies (20)(21)(22). In this manner, we identified the relevant ␤-lactamases for the entire collection of 1,086 Gram-negative clinical isolates.…”

mentioning

confidence: 97%

“…In addition, there were 116 clinical strains of various enterobacterial species selected from a reference collection with various ␤-lactamases and included the 18 isolates without ESBLs or carbapenemases. The nonfermenter isolates tested were clinical isolates from a worldwide collection of Acinetobacter baumannii complex isolates (n ϭ 200; 101 were resistant to at least one carbapenem), S. maltophilia (n ϭ 25 with bla L1 ), and P. aeruginosa (n ϭ 27) isolates with bla VIM , bla PDC , and/or porin OprD deletions from hospitals in the Cleveland, OH, area (6,(20)(21)(22). All A. baumannii complex isolates and a subset of the K. pneumoniae isolates were sequenced by whole-genome sequencing (WGS) using paired-end NexteraXT libraries and an Illumina NextSeq sequencer (2ϫ 150 bp) to ϳ100-fold coverage.…”

mentioning

confidence: 99%

See 1 more Smart Citation

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Jacobs

Abdelhamed

Good

et al. 2019

Antimicrob Agents Chemother

Self Cite

100

View full text Add to dashboard Cite

The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant Acinetobacter baumannii complex, Stenotrophomonas maltophilia, Pseudomonas aeruginosa, and Enterobacteriaceae strains was determined by microdilution in iron-depleted Mueller-Hinton broth. The MIC 90 s against A. baumannii, S. maltophilia, and P. aeruginosa were 1, 0.25, and 0.5 mg/ liter, respectively. Against Enterobacteriaceae, the MIC 90 was 1 mg/liter for the group harboring OXA-48-like, 2 mg/liter for the group harboring KPC-3, and 8 mg/liter for the group harboring TEM/SHV ESBL, NDM, and KPC-2.

show abstract

mentioning

confidence: 97%

mentioning

confidence: 99%

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Jacobs

Abdelhamed

Good

et al. 2019

Antimicrob Agents Chemother

Self Cite

100

View full text Add to dashboard Cite

show abstract

“…every 8h) in combination with ATM (2g i.v. every 8 h) for 48 days was demonstrated for a young renal transplant patient with S. maltophilia resistant to SXT, meropenem and CAZ [11]. In our research, CAZ/AVI has been demonstrated to inhibit the growth of about half of the CAZ-NS isolates (48.48%, 16/33), still showing high-level resistance (MIC: 64/4 µg/mL) in 10 isolates.…”

Section: Bactericidal Activities Of Caz/avi and Atm/avi Against S Mamentioning

confidence: 54%

“…L1 is a class B3 metallo-β-lactamase (MBL) that hydrolyzes carbapenems and other β-lactams, with the important exception of the monobactam aztreonam (ATM), and is resistant to all clinically available β-lactams [1,8,9]. L2 is a class A cephalosporinase that confers resistance to extended-spectrum cephalosporins and ATM but can be inhibited by commercially available serine-β-lactamase inhibitors such as clavulanic acid and avibactam [1,2,11,12]. Avibactam (AVI) is a non β lactam, βlactamase inhibitor without intrinsic antibacterial activity, but offers a broader β-lactamase inhibition pro le compared with any other recently used serine βlactamase inhibitors [13].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of the activity of Ceftazidime-avibactam and Aztreonam-Avibactam against 76 Stenotrophomonas maltophilia isolates from a teaching hospital in Chongqing

Lin¹,

Zou²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Treatment options for Stenotrophomonas maltophilia (S. maltophilia) infections were limited. We assessed the efficacy of ceftazidime-avibactam (CAZ-AVI) and aztreonam-avibactam (ATM-AVI) against a selection of 76 S. maltophilia out of the 1179 strains isolated from the First Affiliated Hospital of Chongqing Medical University during 2011-2018. Methods: We investigated the antimicrobial resistance profiles of the 1179 S. maltophilia clinical isolates from the first affiliated hospital of Chongqing Medical University during 2011-2018, a collection of 76 isolates of which were available for further study of microbiological characterization. Minimum inhibitory concentrations (MICs) of ceftazidime (CAZ), ceftazidime-avibactam (CAZ-AVI), aztreonam (ATM) and aztreonam-avibactam (ATM-AVI) were determined via the broth microdilution method. We deemed that CAZ-AVI or ATM-AVI was more effective in vitro than CAZ or ATM alone when CAZ-AVI or ATM-AVI led to a category change from “Resistant” with CAZ or ATM alone to “Susceptible” or “Intermediate” with CAZ-AVI or ATM-AVI, or if the MIC of CAZ-AVI or ATM-AVI was at least 2-fold lower than the MIC of CAZ or ATM alone. Results: For the 76 clinical isolates included in the study, MICs of CAZ, ATM, CAZ-AVI and ATM-AVI ranged from 0.03-64, 1-1024, 0.016-64, and 0.06-64 μg/mL, respectively. In combined therapy, AVI was effective at restoring the susceptibility of 48.48% (16/33) and 89.71% (61/68) of S. maltophilia to CAZ and ATM, respectively. Furthermore, CAZ-AVI showed better results in terms of the proportion of susceptible isolates (77.63% vs.56.58%, P<0.001), MIC50 (2μg/mL vs. 8μg/mL, P<0.05), and MIC distribution (P<0.001) when compared to CAZ. According to our definition, CAZ-AVI was more effective in vitro than CAZ alone for 84.21% of the isolates. Similarly, ATM-AVI also showed better results in terms of the proportion of susceptible isolates (90.79%vs. 10.53%, P<0.001), MIC50 (2μg/mL vs. 64μg/mL, P<0.001), and MIC distribution (P<0.001) when compared to ATM. According to our definition, ATM-AVI was also more effective in vitro than ATM alone for 97.37% of the isolates. Conclusions: AVI potentiated the activity of both CAZ and ATM against S. maltophilia clinical isolates in vitro. We demonstrated that CAZ-AVI and ATM-AVI are both useful therapeutic options to treat infections caused by S. maltophilia.

show abstract

“…Stenotrophomonas maltophilia is an arising opportunistic pathogenic microorganism, systematic classified by the WHO as one of the governing multidrug-resistant pathogen in a hospital ward (1). Stenotrophomonas maltophilia is a Gram-negative environmental bacterium that can cause respiratory tract infections with cystic fibrosis, associated with bloodstream and urinary tract infections.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic Resistance Surveillance of Clinical Isolates of Stenotrophomonas maltophilia Strains in the Central South of China from 2016 to 2019

Yang

Yan

Chen

et al. 2020

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Due to the difficulty of treatment caused by its numerous mechanisms of resistance, only four kinds of antibiotics are recommended for the therapy of Stenotrophomonas maltophilia infections associated with significant morbidity and mortality. Objectives: In this four-year study, we aimed to determine the evolution of drug resistance to S. maltophilia base on drug classification guidelines recommended by the Institute of Clinical and Laboratory Standards. Methods: A total of 1876 strains of S. maltophilia was separated from multifarious clinical specimens among January 2016 and December 2019. VITEK 2 Compact microbial system was used for speciation level identification and antibiotic sensitivity test. Results: A total of 1876 strains of S. maltophilia strains were separated from sputum specimen type (70.63%), Followed by bronchial (6.18%), blood (4.16%), and bronchoalveolar lavage samples (4.32%). Moreover, 695 strains of S. maltophilia strains were separated from intensive care unit (ICU) department (37.05%), and then neurosurgery ward (10.66%), integrative Chinese and western medicine ward (7.25%), general surgery ward (6.66%). The results of minocycline antibiotic of S. maltophilia with a drug resistance rate of 0.3%. From 2016 to 2019, the resistance rate of cefoperazone/sulbactam decreased from 20.8% to 15.2%, the resistance rate of trimethoprimsulfametoxasole decreased from 7.9% to 4.5%. The resistance rate of minocycline fluctuate in 0.0%% between 0.7%. However, the resistance rate of levofloxacin increased from 7.7% to 8.0%. Conclusions: In this study, S. maltophilia was detected in a variety of specimen types of different clinical departments, with the most detected in ICU patients and sputum specimen. S. maltophilia was sensitive to minocycline and levofloxacin, but the situation of cefoperazone/sulbactam resistance was not optimistic. The results of this study indicate that minocycline is considered to be the most effective antibiotic for the treatment of S. maltophilia. Therefore, we still need to strengthen the drug resistance monitoring, timely acquisition of S. maltophilia drug resistance changes, and actively take effective measures to deal with the drug resistance of S. maltophilia.

show abstract

Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam

Cited by 58 publications

References 17 publications

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases

In Vitro Evaluation of the activity of Ceftazidime-avibactam and Aztreonam-Avibactam against 76 Stenotrophomonas maltophilia isolates from a teaching hospital in Chongqing

Antibiotic Resistance Surveillance of Clinical Isolates of Stenotrophomonas maltophilia Strains in the Central South of China from 2016 to 2019

Contact Info

Product

Resources

About